Fig 1: Expression of Notch ligand, Jagged1 (Jag1) in relation to endothelial cells and mural cells in the peri-implantation uterus. H&E and double staining IF of E3.5 (A – D) and E6.5 (E – H) uterine sections. Ovals indicate areas of the uteri magnified (B1 – D1, F1 – H1). (A) H&E at E3.5 highlighting the luminal epithelium (arrows), inner circular and outer longitudinal myometrium [dashed bracket (myo)], endometrial stroma (st) and serosa (s). (B – D) Jag1+ cells are observed throughout the endometrial stroma and in the myometrium (boxes). (B) Jag1 and CD31. Jag1 is expressed in CD31+ ECs in the stroma and myometrium. (C) Jag1 and NG2. Jag1 is expressed on a subset of NG2+ mural cells in the stroma (arrowheads in C1). (D) Jag1 and PDGFR-β. Jag1 is expressed on a subset of PDGFR-β+ mural cells in the stroma (arrowheads in D1). (E) H&E at E6.5 highlighting the embryo (e), inter-implantation sites (i), and myometrium (myo). (F – H) At E6.5, Jag1+ cells are observed in decidua and myometrium. (F) Jag1 and CD31. Jag1 is expressed in CD31+ ECs of spiral arteries (box) in the mesometrial decidua and in large vessels in the anti-mesometrial decidua and myometrium. (G) Jag1 and NG2 staining. Jag1 is expressed on a subset of NG2+ mural cells in the mesometrial decidua (arrowhead in G1). (H) Jag1 and PDGFR-β. PDGFR-β+ mural cells surround Jag1+ cells in the decidua. DAPI identifies all nuclei in IF images. am, anti-mesometrial; m, mesometrial. Bar in A and E =100 μm. Bar in B – D and F – H =500 μm. Bar in B1 – D1 and F1 – H1 = 50 μm.
Fig 2: PDGF induced phosphorylation events in cells of different Lrig2 genotypes.Wild-type, heterozygous, or Lrig2-deficient MEFs were serum starved for 24 hours followed by stimulation with 50 ng/ml PDGF-BB for different times. (A–N) Cells were untreated or stimulated with 50 ng/ml PDGF-BB for 10 minutes followed by cell fixation and analysis of the phosphorylation status of respective Pdgfr by in situ proximity ligation assay (PLA). Phosphorylated Pdgfr was visualized using fluorescence (red spots). Cell nuclei were counter-stained with DAPI (blue). (A–F) Representative PLA images of phosphorylated Pdgfrα (red spots) in un-stimulated (A–C) or PDGF-BB stimulated (D–F) cells of the indicated Lrig2 genotypes. (G–L) Representative PLA images of phosphorylated Pdgfrβ (red spots) in non-stimulated (G–I) or PDGF-BB-stimulated (J–L) cells of the indicated Lrig2 genotypes. (M) Quantification of PLA spots for phosphorylated Pdgfrα. Shown are the means from three independent experiments, including wild-type (Lrig2E12+/+, n=8), heterozygous (Lrig2E12+/-, n=9), and Lrig2-deficient (Lrig2E12-/-, n=6) cell lines from three different litters, with standard deviations indicated by error bars. (N) Quantification of PLA spots for phosphorylated Pdgfrβ. Shown are the means from three independent experiments, including wild-type (Lrig2E12+/+, n=8), heterozygous (Lrig2E12+/-, n=9), and Lrig2-deficient (Lrig2E12-/-, n=5) cell lines from three different litters, with standard deviations indicated by error bars. There were no differences observed in the levels of activated Pdgfrα or Pdgfrβ between cells of different genotypes. (O–Q) Cell lysates from cells that had been untreated or treated with 50 ng/ml PDGF-BB for 15 minutes were analyzed through Western blotting with antibodies against the indicated proteins. (O) A representative Western blot is shown of Akt, Erk1/2, phosphorylated Akt (pAkt), and phosphorylated Erk1/2 (pErk1/2) using cell lysates from cells of the indicated Lrig2 genotypes that had been untreated (-) or treated (+) with PDGF-BB. (P) Quantification of pAkt/Akt-ratios for non-stimulated and stimulated cells, respectively. Shown are the means from three independent experiments, including wild-type (n=8), heterozygous (n=9), and Lrig2-deficient (n=5) cell lines from three different litters, with standard deviations indicated by error bars. (Q) Quantification of pErk1/2/Erk1/2-ratios for non-stimulated and stimulated cells, respectively. Shown are the means and corresponding standard deviations as for P.
Fig 3: Pdgfr levels in serum-starved primary MEFs.Wild-type (Lrig2E12+/+), heterozygous (Lrig2E12+/-), or Lrig2-deficient (Lrig2E12-/-) MEF cell lines were serum-starved for the indicated times followed by analysis of Pdgfr levels using immunofluorescence microscopy (A–H) or immunoblotting (I–L). (A–H) Cells were serum starved for 24 hours followed by analysis of Pdgfrα (A–D) or Pdgfrβ (E–H) levels using immunofluorescence microscopy. Pdgfr immunoreactivity was visualized with Alexa-conjugated secondary antibodies (red), and the nuclei were counter-stained with DAPI (blue). (D, H) Quantifications of the Pdgfrα and Pdgfrβ immunofluorescence levels, respectively. Shown are the means from three independent experiments, including wild-type (n=8), heterozygous (n=9), and Lrig2-deficient (n=6) cell lines from three different litters, with standard deviations indicated by error bars. There were no differences observed in Pdgfrα or Pdgfrβ protein levels, as determined by quantitative immunofluorescence microscopy, between cells of different Lrig2 genotypes. (I–L) Cells were serum starved for 0, 6, 12 or 24 hours followed by cell lysis and Western blot analyses with antibodies against Pdgfrα, Pdgfrβ, or, as a loading control, actin. Representative immunoblots of Pdgfrα (I) and Pdgfrβ (J) in wild-type (Lrig2E12+/+), heterozygous (Lrig2E12+/-), and Lrig2-deficient (Lrig2E12-/-) cells after 0 or 24 hours of serum starvation. (K–L) Quantifications of Pdgfrα (K) and Pdgfrβ (L) immunoblots in wild-type, heterozygotes and Lrig2-deficient cells after 0, 6, 12 and 24 h starvation. Shown are the means from three independent experiments including wild-type (n=8), heterozygous (n=9), and Lrig2-deficient (n=6) cell lines from three different litters, with standard deviations indicated by error bars. There were no differences observed in Pdgfrα or Pdgfrβ protein levels as determined by immunoblotting, between cells of different Lrig2 genotypes.
Fig 4: Characterization of endothelial cells and mural cells in the post-implantation uterus. H&E and double staining IF of E6.5 uterine sections through implantation sites, showing inter-embryonic regions and central parts of the decidua. Ovals indicate areas of the uteri magnified (B1 – E1). (A) H&E at E6.5 highlighting the embryo (e), inter-implantation sites (i), myometrium [dashed bracket (myo)], and decidua, which is between the embryo and dashed line. (B – E) CD31+ ECs are observed throughout the decidua, inter-implantation sites, and myometrium. (B) CD31 and NG2 staining. NG2+ mural cells are associated with CD31+ ECs in the myometrium (boxes) and in the decidua (arrowheads in B1). NG2+ mural cells are abundant in the anti-mesometrial (am) decidua and sparse in the mesometrial (m) decidua. (C) CD31 and PDGFR-β staining. PDGFR-β+ murals cells are associated with CD31+ ECs in the anti-mesomestrial decidua and myometrium. PDGFR-β + mural cells are abundant in the anti-mesometrial decidua and sparse in the mesometrial decidua (D) CD31 and desmin staining. Desmin+ cells are observed throughout the decidua and myometrium. (E) CD31 and SMA staining. SMA+ smooth muscle cells are observed in the myometrium and are not associated with CD31+ decidual ECs. DAPI identifies all nuclei in IF images. Bar in A = 100 μm. Bar in B – E = 500 μm. Bar in B1 – E1 = 50 μm.
Fig 5: Location of Notch2 (N2) in relation to endothelial cells and mural cells in the peri-implantation uterus. H&E and double staining IF of E3.5 (A – D) and E6.5 (E – H) uterine sections. Ovals indicate areas of the uteri magnified (B1 – D1, F1 – H1). (A) H&E at E3.5 highlighting the luminal epithelium (arrows), and myometrium (myo), and endometrial stroma (st). (B – D) Notch2+ cells are observed throughout the stroma, myometrium and serosa (s), with low levels of Notch2 in endometrial glands (g). (B) Notch2 and CD31. Notch2+ cells in association with CD31+ ECs are scattered sparsely throughout the endometrium (arrrowhead in B1) and serosa (s). (C) Notch2 and PDGFR-β. Notch2 is not associated with PDGFR-β+ mural cells in the stroma and myometrium. (D) Notch2 and SMA. SMA+ smooth muscle cells are observed adjacent to Notch2+ cells in myometrium. Some uterine smooth muscle cells express both Notch2 and SMA. (E) H&E at E6.5 highlighting the embryo (e), inter-implantation sites (i), and myometrium (myo). (F – H) Notch2+ cells are observed throughout the myometrium. (F) Notch2 and CD31. Notch2 is not expressed in CD31+ decidual vessels. (G) Notch2 and PDGFR-β. Notch2 is not associated with PDGFR-β in the decidua or myometrium. (H) Notch2 and SMA staining. SMA+ smooth muscle cells are observed adjacent to Notch2+ cells in myometrium. Some uSMCs express both Notch2 and SMA. DAPI identifies all nuclei in IF images. am, anti-mesometrial; m, mesometrial. Bar in A and E =100 μm. Bar in B – D and F – H =500 μm. Bar in B1 – D1 and F1 – H1 = 50 μm.
Supplier Page from Abcam for Anti-PDGFR beta antibody [APB5]